The first patient enrolled in the ReITIrate study evaluating immune tolerance induction with Elocta®
Swedish Orphan Biovitrum AB (publ) (Sobi™) announces today that the first patient has been enrolled in the open-label, multicentre ReITIrate study (NCT03103542). The ReITIrate study is designed to investigate the immune tolerance induction (ITI) potential of Elocta® (efmoroctocog alfa) in patients with haemophilia A who have developed inhibitors which have failed to be resolved with other therapies. The study is being performed under the collaboration agreement with Bioverativ Therapeutics Inc. The development of antibodies (inhibitors) that neutralise the effect